These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 20230061

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The Glu143 Residue Might Play a Significant Role in T20 Peptide Binding to HIV-1 Receptor gp41: An In Silico Study.
    Alaofi AL.
    Molecules; 2022 Jun 20; 27(12):. PubMed ID: 35745059
    [Abstract] [Full Text] [Related]

  • 23. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.
    Chong H, Xu S, Zhang C, Nie J, Wang Y.
    J Clin Virol; 2009 Jul 20; 45(3):255-8. PubMed ID: 19487156
    [Abstract] [Full Text] [Related]

  • 24. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
    Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B.
    J Virol; 2004 Nov 20; 78(22):12428-37. PubMed ID: 15507629
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells.
    Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Kräusslich HG, Dittmar MT.
    Virology; 2005 Mar 15; 333(2):251-62. PubMed ID: 15721359
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
    Carmona R, Pérez-Alvarez L, Muñoz M, Casado G, Delgado E, Sierra M, Thomson M, Vega Y, Vázquez de Parga E, Contreras G, Medrano L, Nájera R.
    J Clin Virol; 2005 Mar 15; 32(3):248-53. PubMed ID: 15722032
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Structural and functional characterization of HIV-1 cell fusion inhibitor T20.
    Zhang X, Ding X, Zhu Y, Chong H, Cui S, He J, Wang X, He Y.
    AIDS; 2019 Jan 27; 33(1):1-11. PubMed ID: 30096076
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.
    Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.
    Protein Sci; 2019 Aug 27; 28(8):1501-1512. PubMed ID: 31228294
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA, Fochtman BC, Rizzo RC, Jacobs A.
    Curr HIV Res; 2016 Aug 27; 14(3):283-94. PubMed ID: 26957202
    [Abstract] [Full Text] [Related]

  • 40. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F, Lu L, Liu Q, Yu X, Wang L, He E, Zou P, Du L, Sanders RW, Liu S, Jiang S.
    Biochim Biophys Acta; 2014 May 27; 1838(5):1296-305. PubMed ID: 24388952
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.